Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Orlistat (Xenical)].

L Crenier1, J Sternon

  • 1Service d'Endocrinologie, Hôpital Erasme et C.U.M.G.-U.L.B.

Revue Medicale De Bruxelles
|August 3, 1999
PubMed
Summary
This summary is machine-generated.

Orlistat, an obesity treatment, inhibits fat absorption, leading to approximately 10% weight loss in one year when combined with a hypocaloric diet. It offers gastrointestinal side effects but is generally well-tolerated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[New antidiabetic medications: at the dawn of a revolution? New therapeutic options for type 2 diabetes are challenged for cardiovascular disease prevention].

Revue medicale de Bruxelles·2017
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

Correlates of fractures in elderly, diabetic outpatients.

Acta clinica Belgica·2015
Same author

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Diabetologia·2013
Same author

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

Diabetologia·2010
Same author

[Varenicline: an aid to smoking cessation therapy].

Revue medicale de Bruxelles·2008
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Obesity Research

Background:

  • Orlistat is a lipase inhibitor, the first in its class for obesity treatment.
  • It reduces dietary fat absorption by inhibiting pancreatic and intestinal lipases.
  • Approximately 30% of ingested fat is excreted undigested at standard dosage.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Orlistat in obese patients.
  • To assess Orlistat's role in weight loss and impact on serum lipid levels.
  • To position Orlistat as a current therapeutic option for obesity.

Main Methods:

  • Double-blind, placebo-controlled studies were conducted.
  • Orlistat was administered with a balanced, mildly hypocaloric diet.

Related Experiment Videos

  • Patient outcomes including weight loss and serum lipid changes were monitored over one year.

    • Main Results:

    • Statistically significant weight loss of approximately 10% was observed in the Orlistat group.
    • Beneficial, though small, changes in serum lipid levels were noted.
    • Gastrointestinal side effects, primarily steatorrhea, were common but generally well-tolerated.

    Conclusions:

    • Orlistat, when combined with a hypocaloric diet, is effective for one-year weight loss in obese patients.
    • The drug presents a viable treatment option for obesity, especially after the withdrawal of other agents.
    • Long-term efficacy and safety data for Orlistat are still needed.